FDA Approves New Antibiotic for Three Different Uses
"The FDA will continue our important work in this area as part of our efforts to protect the public health."
- "The FDA will continue our important work in this area as part of our efforts to protect the public health."
- Zevtera's efficacy in treating SAB was evaluated in a randomized, controlled, double-blind, multinational, multicenter trial .
- In the trial, researchers randomly assigned 390 subjects to receive Zevtera (192 subjects) or daptomycin plus optional aztreonam [the comparator] (198 subjects).
- A total of 69.8% of subjects who received Zevtera achieved overall success compared to 68.7% of subjects who received the comparator.